Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Pharma · GSK Taiwan
№ 93 · The GSK Taiwan dossier

GSK Taiwan

葛蘭素史克台灣
Parent: GSK plc (LSE: GSK; NYSE: GSK)
Readiness
95
Greenfield
Capped at 95. High confidence — AOR sourced within 3y · high-confidence research.
Workspace · saved locally in your browser
Pipeline status
Your notes · GSK Taiwan
Saves on blur. Stored in your browser only — not synced.

Pure-play Rx + vaccines post-2022 Haleon spin-off. TW marketing is therapy-area-led, HCP-channel-heavy by regulation. Adult-vaccine portfolio (Shingrix, Arexvy, Bexsero) is the strongest consumer-facing growth surface. Disease-awareness unbranded campaigns (shingles, RSV, COPD) used to lift awareness without Rx DTC violations. Globally Publicis-locked since 2018.

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 95
score breakdown
AOR 8y with Publicis Media (platformGSK bespoke unit) — Publicis Health (Saatchi Wellness, Digitas Health, Razorfish Health, Heartbeat, Langland) on creativeaor_anniversary_5y+50
Intel depth (6 wedges · M&A)research_depth+45
Total · capped 9595
30-day signal trajectory
0 signals · spend N/A
Intel wedges
6/8
6 of 8 wedges corroborated. Research confidence: high — global Publicis platformGSK consolidation since Oct 2018 is publicly documented across Fierce Pharma, AdWeek, MM+M, Campaign Live, Mediapost. The user-brief assertion of 'WPP since 2019' is incorrect per public record..
Open playbook →
Recommended posture
Pitch now.
WPP HAD GSK globally pre-2018 — there is a relationship history to revive at the TW market level even with Publicis as global incumbent